by Portfolio Grader | February 7, 2014 8:15 am
The grades of eight pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Forest Laboratories, Inc. (FRX) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Forest Laboratories develops, manufactures, and sells both branded and generic forms of ethical products which require a physician’s prescription. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, Earnings Revisions and Earnings Surprise, FRX also gets A’s. For more information, get Portfolio Grader’s complete analysis of FRX stock.
This week, Merck & Co., Inc. (MRK) pushes up from a B to an A rating. Merck is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. Shares of MRK have increased 7.5% over the past month, better than the 1.7% decrease the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of MRK stock.
Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Teva Pharmaceutical Industries Ltd. is engaged in the provision of pharmaceutical services. It operates through the following business divisions: Generic, Branded, and Over-the-Counter (OTC). The Generic division involves the manufacture and sale of generic products such as tablets, capsules, ointme… For more information, get Portfolio Grader’s complete analysis of TEVA stock.
Watson Pharmaceuticals (WPI) gets a higher grade this week, advancing from a B last week to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Flamel Technologies SA Sponsored ADR’s (FLML) ratings are looking better this week, moving up to an A from last week’s B. Flamel Technologies develops polymer technologies for applications such as drug delivery, biomaterials, and agrochemicals. For more information, get Portfolio Grader’s complete analysis of FLML stock.
Akorn, Inc. (AKRX) is seeing ratings go up from a B last week to an A this week. Akorn engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. For more information, get Portfolio Grader’s complete analysis of AKRX stock.
Nektar Therapeutics (NKTR) shows solid improvement this week. The company’s rating rises from a C to a B. Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. For more information, get Portfolio Grader’s complete analysis of NKTR stock.
This week, AcelRx Pharmaceuticals, Inc.’s (ACRX) ratings are up from a C last week to a B. Acelrx focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. For more information, get Portfolio Grader’s complete analysis of ACRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2014/02/8-pharmaceutical-stocks-to-buy-now-frx-mrk-teva/
Short URL: http://invstplc.com/1o07Llm
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.